Emergent translational immunology suggests that pan‐JAKi, JAK1 inhibition, or Tyk2 inhibition works for SpA‐related arthropathy, and our current findings suggest that JAKi blocked entheseal lymphocytes key proinflammatory cytokines including TNFα, IL‐17A, and IL‐17F in keeping with the known robust efficacy of JAKi in SpA‐related arthropathy.4, 8. This evidence concerns the gene TYK2 and arthropathy.